**Table S1.** Response to treatment with lenvatinib and atezolizumab plus bevacizumab for hepatocellular carcinoma.

|  |  |  |
| --- | --- | --- |
| **Evaluation**  **(RECIST version 1.1)** | **Atezo+Bev**  ***n (%)***  ***(n=113)*** | **LEN**  ***n (%)***  ***(n=131)*** |
| Complete response | 1 (0.8) | 2 (1.5) |
| Partial response | 22 (19.5) | 33 (25.1) |
| Stable disease | 67 (59.3) | 82 (62.6) |
| Progressive disease | 23 (20.4) | 14 (10.7) |
| Objective response rate (%) | 20.4 | 26.7\* |
| Disease control rate (%) | 79.6 | 89.3 |

LEN, lenvatinib; RECIST, Response Evaluation Criteria in Solid Tumors